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PRenal Function in Acute Coronary Syndrome
Cockcroft-Gault Versus
Modification of Diet in Renal Disease
Importance of Glomerular Filtration Rate Formula
for Classification of Chronic Kidney Disease in Patients
With Non–ST-Segment Elevation Acute Coronary Syndromes
Chiara Melloni, MD, MHS,* Eric D. Peterson, MD, MPH,* Anita Y. Chen, MS,*
Lynda A. Szczech, MD, MSCE,* L. Kristin Newby, MD, MHS,* Robert A. Harrington, MD,*
W. Brian Gibler, MD,† E. Magnus Ohman, MD,* Sarah A. Spinler, PHARMD, FCCP,‡
Matthew T. Roe, MD, MHS,* Karen P. Alexander, MD*
Durham, North Carolina; Cincinnati, Ohio; and Philadelphia, Pennsylvania
Objectives Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non–ST-segment eleva-
tion acute coronary syndromes (NSTE ACS) patients.
Background Assessment of GFR is important for antithrombotic dose adjustment in NSTE ACS patients.
Methods We assessed estimated glomerular filtration rate (eGFR) with Cockcroft-Gault (C-G) and Modification of Diet in
Renal Disease (MDRD) formulae in 46,942 NSTE ACS patients from 408 CRUSADE (Can Rapid risk stratification
of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of
Cardiology/American Heart Association Guidelines) hospitals. Formula agreement was shown continuously and
by chronic kidney disease (CKD) stages. We determined in-hospital outcomes and the association between anti-
thrombotic dose adjustment and bleeding for moderate CKD as determined by each formula.
Results The median (interquartile range [IQR]) eGFR was 53.2 ml/min (34.7, 75.1 ml/min) by C-G and 65.8 ml/min
(47.6, 83.5 ml/min) by MDRD. The mean eGFR was higher with MDRD (9.1 ml/min), but this difference was
greater in age, weight, and gender subgroups. Chronic kidney disease classification differed in 20% of the popu-
lation and altered when antithrombotic dose adjustment was required by C-G versus MDRD (eptifibatide: 45.7%
vs. 27.3%; enoxaparin: 19.0% vs. 9.6%).
Conclusions Important CKD disagreements occur in20% of acute coronary syndrome patients, affecting dosing adjustments in
those already susceptible to bleeding. Dosing based on C-G formula is preferable, particularly in the small, female, or
elderly patient. (J Am Coll Cardiol 2008;51:991–6) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.045m
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Khronic kidney disease (CKD) is a powerful predictor of
dverse events among non–ST-segment elevation acute coro-
ary syndromes (NSTE ACS) patients (1–3). Estimated glo-
rom the *Division of Cardiology and Duke Clinical Research Institute, Duke
niversity Medical Center, Durham, North Carolina; †Department of Emergency
edicine, University of Cincinnati College of Medicine, Cincinnati, Ohio; and
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia,
hiladelphia, Pennsylvania. The CRUSADE initiative is a National Quality Im-
rovement Initiative of the Duke Clinical Research Institute. The CRUSADE
nitiative is funded by the Schering-Plough Corporation. The Bristol-Myers
quibb/Sanofi Pharmaceuticals Partnership provides additional funding support.
illennium Pharmaceuticals, Inc., funded part of this work. This work is also
upported, in part, by a grant from the National Institute on Aging (R01 AG025312-
1A1, PI Peterson). More information on CRUSADE can be found at http://
ww.crusadeqi.com.(
Manuscript received May 29, 2007; revised manuscript received October 5, 2007,
ccepted November 8, 2007.erular filtration rate (eGFR) is necessary to classify CKD and
ose-adjust renally excreted antithrombotic drugs. Cockcroft-
ault (C-G) (4) and Modification of Diet in Renal Disease
quations (MDRD) (5) are 2 widely available formulae in
linical practice. However, there is continued debate over
hich formula more accurately estimates renal function (6,7).
Neither formula was developed or validated in patients
ith cardiac disease; moreover, they differ in variables and
oefficients. The C-G formula is recommended by the
merican College of Cardiology/American Heart Associa-
ion (ACC/AHA) guidelines and the Food and Drug
dministration and is easier to calculate at the bedside (8,9).
he MDRD equation is recommended by the National
idney Foundation as more accurate for estimating GFR
6,10) and is currently generated in many laboratory reports.
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GFR Formulae in NSTE ACS March 11, 2008:991–6Despite its importance in the
care of cardiac patients, eGFR for-
mula comparisons in this popula-
tion have not been performed.
Therefore, using data from the
CRUSADE (Can Rapid Risk
Stratification of Unstable Angina
Patients Suppress Adverse Out-
comes with Early Implementation
of the ACC/AHA Guidelines)
quality improvement initiative, the
agreement between formulae in
determining eGFR and CKD
stages was described. The magni-
tude and implication of formula
disagreements were explored in re-
lation to antithrombotic dose and
dose-associated risk of bleeding. In
so doing, we sought to determine
the preferable formula for the as-
sessment of eGFR in a cardiac
population in relation to dosing
and bleeding.
ethods
he CRUSADE initiative is an observational registry of
igh-risk patients with NSTE ACS admitted to U.S.
ospitals since November 2001. Criteria for inclusion in
RUSADE include acute ischemic symptoms lasting for 10
in within 24 h of hospital arrival and 1 or more high-risk
eatures: ST-segment depression 0.5 mm, transient ST-
egment elevation 0.5 to 1.0 mm (lasting for 10 min),
nd/or positive cardiac markers (elevated troponin I or T
nd/or creatine kinase-MB greater than the upper limit of
ormal for the local laboratory). Patients are ineligible for
RUSADE if they transfer into a participating hospital
24 h after the last episode of ischemic symptoms. Details
f CRUSADE data collection are described elsewhere (11).
tudy population. The analysis population included pa-
ients admitted to 408 U.S. hospitals from January 2004
hrough March 2005. From 49,595 high-risk NSTE ACS
atients, we excluded 1,625 (3.3%) with missing serum
reatinine, 1,000 (2.1%) with missing data for key variables
age, gender, weight, or race) used to calculate eGFR, and
8 (0.06%) with serum creatinine values15 mg/dl, leaving
final study population of 46,942 patients. For the analysis
f in-hospital outcomes, 5,724 (12.2%) transfer-out patients
ere excluded. For the major bleeding analysis, 4,775
10.2%) patients who underwent coronary artery bypass
raft surgery and 1,289 (2.7%) with baseline hematocrit
26% were excluded.
ategorization of CKD. Serum creatinine, lean body
eight, race, gender, and age were used to determine eGFR
y C-G (4) and abbreviated MDRD (5) formula across the
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
BMI  body mass index
CI  confidence interval
CKD  chronic kidney
disease
C-G  Cockcroft-Gault
eGFR  estimated
glomerular filtration rate
GFR  glomerular filtration
rate
GP  glycoprotein
MDRD  Modification of
Diet in Renal Disease
NSTE ACS  non–ST-
segment elevation acute
coronary syndromes
OR  odds rationtire population. Cockcroft-Gault calculates creatinine clearance as CrCl (ml/min)  ([{140  age in years} 
ody weight in kg]/{72  Cr in mg/dl})  0.85 (female
ender), and the abbreviated MDRD formula estimates
FR as (ml/min/1.73 m2 of body surface area)  186 
serum creatinine in mg/dl)1.154  (age in years)0.203 
0.742 if female gender)  (1.210 if African American).
ockcroft-Gault formula was adjusted for lean body weight to
mprove glomerular filtration rate (GFR) estimation (12). Both
ormulae provide estimated GFR (ml/min). Patients were
lassified into CKD stages: normal/mild CKD (eGFR 60
l/min), moderate CKD (eGFR 30 to 59 ml/min), and severe
KD and kidney failure (eGFR 30 ml/min) (6).
tatistical analysis. The median difference between eGFR
ormulae was determined on a per-patient basis overall and
mong subgroups by age (75 vs. 75 years), gender, and
ody mass index (BMI) (25 kg/m2, 25 to 30 kg/m2, 30
g/m2). Spearman correlation was used to evaluate the
elationship between eGFR by C-G versus MDRD formu-
ae. A scatterplot showing the correlation between eGFR
etermined by C-G and MDRD with parallels to 60
l/min on each axis demonstrates 4 groups of relative
greement. The fitted line on the plot was obtained from a
eneralized estimating equations spline regression model of
DRD on C-G (13). Next, we summarized the prevalence
f CKD stages by each formula. Because most disagree-
ents were in moderate CKD, we chose “moderate CKD
greement” as the reference group for comparison with
moderate CKD by MDRD only” (eGFR 30 to 59 ml/min
y MDRD but60 ml/min by C-G), and “moderate CKD
y C-G only” (eGFR 30 to 59 ml/min by C-G but 60
l/min by MDRD). To understand the implications of
isagreement, we compared baseline characteristics and
dverse in-hospital outcomes of death and major bleeding
y moderate CKD agreement groups. Major bleeding was
efined as any intracranial hemorrhage, red blood cell
ransfusion (2 U), or absolute drop in hematocrit of at
east 12%.
We then evaluated the proportion of patients who re-
uired dose adjustment for glycoprotein (GP) IIb/IIIa
nhibitors (eptifibatide and tirofiban) and low-molecular-
eight heparin (enoxaparin) if eGFR were estimated by
ach formula (8,9). An excess dose of GP IIb/IIIa inhibitor
as considered as a full dose of tirofiban if eGFR 30
l/min or of eptifibatide if eGFR 50 ml/min. An excess
ose of enoxaparin was considered to be 1 mg/kg every 12 h
f eGFR 30 ml/min. For those treated with GP IIb/IIIa
nhibitors or enoxaparin, major bleeding was shown for “no
xcess dose” and “excess dose” according to the categoriza-
ion produced by each formula. In a validation analysis, rates
f bleeding were consistent across BMI subgroups, empha-
izing that anthropomorphic considerations did not alter
hese results. Adjusted rates of major bleeding for excess and
o excess groups by each formula were determined. Adjust-
ent was performed for age, renal insufficiency, gender,
ongestive heart failure, and systolic blood pressure (14).
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March 11, 2008:991–6 GFR Formulae in NSTE ACSContinuous variables are reported as medians (interquar-
ile range [IQR]) compared using the Wilcoxon 2-sample
est. Categorical variables are reported as frequencies com-
ared using chi-square tests. A p value 0.05 was consid-
red statistically significant. All analyses were performed by
sing SAS software version 8.2 (SAS Institute, Cary, North
arolina).
esults
omparison between C-G and MDRD formulae.
lthough there was generally good correlation between
-G andMDRD estimates of GFR (r 0.89; p 0.0001),
he C-G formula calculated a lower median (IQR) eGFR
or the population (C-G median 53.2 ml/min [IQR 34.7,
5.1 ml/min] vs. MDRD median 65.8 ml/min [IQR 47.6,
3.5 ml/min]). The difference between eGFRs (MDRD 
-G) on a per-patient basis was median 9.1 ml/min (IQR
.9, 18.1 ml/min); however, elderly and female subgroups
ad an even lower eGFR by C-G, making subgroup
ifferences more notable (Fig. 1). The younger (75 years)
ale subgroup demonstrated the highest correlation be-
ween formulae (median 1.1 ml/min [IQR 5.3, 8.7 ml/
in]) (Fig. 1). Older (75 years) male subjects had a larger
edian difference (median 12.5 ml/min [IQR 7.1, 19.4
l/min]) similar to younger (75 years) female subjects
median 12.4 ml/min [IQR 5.0, 20.2 ml/min]). The largest
ifference was in the older (75 years) female subjects
median 18.6 ml/min [IQR 11.9, 26.6 ml/min]). The
ifference between formulae was also greater with smaller
MI 25 kg/m2 (median 11.3 ml/min [IQR 3.5, 19.9
l/min]) and narrowed for the obese, BMI 30 kg/m2
median 6.3 ml/min [IQR 1.7, 15.3 ml/min]) (Fig. 2).
Using the C-G formula, 41.2% (n  19,349) had normal
r mild CKD, 39.8% (n 18,657) had moderate CKD, and
9% (n  8,936) had severe CKD or kidney failure. Using
Figure 1 Median Differences in eGFR (ml/min) Between
MDRD and C-G Formulae Overall and by Subgroups
Data are truncated at 30 and 30. C-G  Cockcroft-Gault; eGFR  esti-
mated glomerular filtration rate; MDRD  Modification of Diet in Renal
Disease.he MDRD formula, 58.9% (n  27,666) had normal orild CKD, 31.5% (n  14,769) had moderate CKD, and
.6% (n  4,507) had severe CKD or kidney failure.
Different CKD classification occurred in 20% of the
opulation. Modification of Diet in Renal Disease identi-
ed 1.2% (n  568) with moderate CKD who were
lassified as normal/mild CKD by C-G, and C-G identified
8.9% (n 8,885) with moderate CKD who were classified
y MDRD as normal/mild CKD. When both formulae had
GFR below 60 ml/min, disagreements occurred when
DRD classified moderate but C-G classified severe CKD
n  4,435) (Fig. 3).
Figure 2 Median Differences in eGFR (ml/min)
Between MDRD and C-G Formulae by BMI Categories
Data are truncated at 30 and 30. BMI  body mass index; other abbrevia-
tions as in Figure 1.
Figure 3 Scatterplot of the Agreement Between C-G
and MDRD Formulae in the Estimation of GFR
Data in the figure represent 1% of a simple random sample of 46,942
patients. Lines drawn at 60 ml/min and 30 ml/min to emphasize categori-
cal chronic kidney disease cut points as well as the linear relationship
between formulae. Line of agreement shown. CrCl  creatinine clearance;
other abbreviations as in Figure 1.
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GFR Formulae in NSTE ACS March 11, 2008:991–6aseline characteristics and clinical outcomes by CKD
greement groups. Compared with the CKD agreement
roup, patients with moderate CKD by MDRD only were
ore often younger, men, white, and obese, whereas pa-
ients with moderate CKD by C-G only were more often
lder, women, nonwhite, and nonobese (Table 1). Patients
n the agreement group had in-hospital adverse outcomes
hat were generally similar to those with moderate CKD by
-G only. Those with moderate CKD by MDRD only had
lower rate of in-hospital adverse outcomes (Table 2).
eed for dose adjustment by MDRD and C-G formu-
ae. The proportion of patients requiring dose adjustment
aried based on the eGFR formula used. For eptifibatide,
djustment was required in 45.7% (n 21,450) by C-G but
7.3% (n  12,822) by MDRD; and for tirofiban and
Patient Baseline Characteristics by CKD Agreem
Table 1 Patient Baseline Characteristics by
Baseline
Characteristics
Agreement
Moderate CKD*
(n  9,766)
Age (yrs) 73 (65, 79)
Male gender (%) 58.9
Race (%)
White 86.2
African American 6.5
Weight (kg) 80.9 (69.9, 93.4)
Height (cm) 170.2 (162.6, 177.8)
BSA (m2) 1.93 (1.78, 2.08)
BMI (kg/m2) 27.7 (24.4, 31.9)
Diabetes (%) 40.2
Hypertension (%) 77.8
Prior MI (%) 33.5
Prior CHF (%) 22.1
Prior PCI (%) 24.9
Prior CABG (%) 25.5
*Moderate chronic kidney disease (CKD): stage 3 (estimated glomerula
moderate CKD agreement versus moderate CKD by Modification of
moderate CKD by Cockcroft-Gault (C-G) only. Continuous variables a
2-sample test.
BMI body mass index; BSA body surface area; CABG coronary
disease; MI  myocardial infarction; PCI  percutaneous coronary int
n-Hospital Clinicalutcomes by CKD Agreement Groups
Table 2 In-Hospital ClinicalOutcomes by CKD Agreement Groups
Outcomes (%)
Agreement
Moderate CKD*
(n  9,766)
Disagreement
Moderate CKD*
MDRD Only
(n  568)
Disagreement
Moderate CKD*
C-G Only
(n  8,782)
Death 5.3 1.2 3.2
Heart failure 10.2 4.0 8.2
RBC transfusion† 10.2 2.6 8.3
Major bleeding†‡ 12.4 4.5 10.1
Moderate CKD: stage 3 (estimated glomerular filtration rate 30 to 59 ml/min); †Among patients
ot undergoing coronary artery bypass; ‡Major bleeding was defined as any intracranial hemor-
hage, red blood cell transfusion (2 U), or absolute drop in hematocrit of at least 12%. All p values
0.0001; p values compare moderate CKD agreement versus moderate CKD by MDRD only ands
oderate CKD agreement versus moderate CKD by C-G only.
RBC  red blood cell; other abbreviations as in Table 1.noxaparin, adjustment was required in 19% (n  8,936) by
-G but just 9.6% (n  4,507) by MDRD.
ctual dose adjustment and major bleeding. Among
atients treated with GP IIb/IIIa inhibitors (n  17,632),
xcess dose by C-G eGFR occurred in 27.3% (n  4,804),
nd excess dose by MDRD eGFR occurred in 12.6% (n 
,221). Major bleeding occurred in 17.8% who received
xcess dose determined by C-G and 21.8% who received
xcess dose determined by MDRD. Major bleeding oc-
urred in 7.4% who received no excess by C-G and 8.5%
ho received no excess by MDRD. The adjusted odds ratios
ORs) for major bleeding with GP IIb/IIIa excess dose
ased on C-G or MDRD were 1.31 (95% confidence
nterval [CI] 1.12 to 1.54) and 1.57 (95% CI 1.35 to 1.84),
espectively.
Among patients treated with enoxaparin (n  2,778),
xcess dose based on C-G occurred in 18.4% (n 511), and
xcess dose by MDRD occurred in 12.6% (n  351). Major
leeding occurred in 17.5% who received excess by C-G,
6.1% who received excess by MDRD, 8.5% who received
o excess by C-G, and 9.3% who received no excess by
DRD. The adjusted ORs of in-hospital major bleeding
or enoxaparin excess based on C-G and MDRD were 1.54
95% CI 1.04 to 2.28) and 1.50 (95% CI 1.06 to 2.14),
espectively.
Across groups defined by BMI, the rate of major bleeding
as consistently higher when an excess dose of GP IIb/IIIa
nhibitors was determined by MDRD, with those in the
owest BMI group having higher rates of bleeding (data not
Groups
Agreement Groups
Disagreement
Moderate CKD*
MDRD Only
(n  568)
Disagreement
Moderate CKD*
C-G Only
(n  8,782)
57 (49, 62) 76 (67, 82)
92.6 44.8
93.5 79.0
1.1 12.8
99.8 (87, 113) 73 (62.6, 85.3)
182.9 (178, 185.4) 162.6 (157.5, 170.2)
2.2 (2.1, 2.4) 1.8 (1.6, 1.9)
29.7 (26.6, 33.4) 26.9 (23.5, 31.2)
27.8 29.1
65.1 72.3
29.8 27.0
8.8 15.0
25.0 19.1
18.0 18.9
on rate 30 to 59ml/min). All p values are0.0001; p values compare
Renal Disease (MDRD) only and moderate CKD agreement versus
rted as medians (interquartile range) compared using the Wilcoxon
ypass grafting; CHF congestive heart failure; CKD chronic kidney
on.ent
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March 11, 2008:991–6 GFR Formulae in NSTE ACSiscussion
n a high-risk NSTE ACS population, CKD is prevalent by
ither the C-G or MDRD formula. However, the median
GFR of the population is higher by MDRD, and catego-
ization of moderate-to-severe CKD is less frequent. C-G
alculates a lower eGFR, particularly in age, gender, and
eight subgroups. More patients requiring dose adjust-
ents are identified by C-G, particularly among subgroups
lready at high risk for bleeding.
KD determination. Chronic kidney disease is common
nd strongly predicts adverse in-hospital outcomes (15,16).
ccurate delineation of CKD may help target aggressive
reatments and limit the risks of therapy (3). Several studies
17,18) using reference indicators to compare C-G and
DRD formulae concluded that MDRD measures eGFR
ore precisely below 60 ml/min but overestimates eGFR in
ubgroups (e.g., elderly), a finding supported by our data.
hether eGFR should be adjusted for body size is less clear
17,19), yet the relationship between the formulae and
utcomes remained consistent across BMI groups in our
ata. Although these formulae are well correlated, their dis-
greement is almost exclusively in the moderate CKD range
nd in female, elderly, and lower BMI patients.
linical implications. Several studies have shown a linear
elationship between eGFR and risk of bleeding (2,3). We
ound that patients with moderate CKD only by C-G had
 rate of major bleeding similar to when there was CKD
greement. This suggests that C-G identifies more patients
verall and that the additional patients classified only by
-G are at similarly high risk.
The high risk of bleeding may be related to renal
ysfunction, but also to excess dosing of antithrombotic
herapy (14,20). The MDRD formula identified one-half as
any patients for dose adjustment as the C-G formula,
articularly excluding those already at high risk of bleeding
14). This shift of 20% of the population across lines for
ose adjustment appears to alter the safety of drugs in
ommunity practice. Guidelines already state that dose
djustments for antithrombotic therapy should be based on
he C-G formula (8,9). Thus, MDRD identifies fewer
atients for dose adjustment and increases the likelihood of
ose-associated bleeding. Although calculating an eGFR is
n important first step, C-G is more conservative and
ndicates the need for dose adjustment more often in at-risk
ubgroups. From a safety perspective, our results support
urrent recommendations for use of C-G formula for anti-
hrombotic dosing in an NSTE ACS population.
tudy limitations. Only baseline creatinine was available,
o variation in creatinine during the hospital stay was not
valuated. Lack of calibration of serum creatinine measure-
ent across hospitals could represent an additional source of
ariation. Excess dose only considered the initial dose, so
ubsequent adjustments were not considered. This analysis
id not compare eGFR with a gold standard. Moreover, we
o not know if eGFR was calculated before dosing or whichormula was used at the point of care. Finally, clinical events
ere not adjudicated.
onclusions
hereas MDRD and C-G formulae are highly correlated,
heir categorical estimations of CKD differ in 20% of an
cute coronary syndrome population. Most disagreement
ccurs in moderate CKD, particularly among older, smaller,
nd female subgroups. These differences translate into more
ntithrombotic dose adjustment by C-G and a lower risk of
leeding. Therefore, safety is enhanced by dosing based on
-G formula, particularly in the elderly, small, or female
atients.
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